Literature DB >> 31913509

Neurocognitive and psychosocial outcomes in adult survivors of childhood soft-tissue sarcoma: A report from the St. Jude Lifetime Cohort.

Ingrid Tonning Olsson1, Tara M Brinkman1,2, Mingjuan Wang3, Matthew J Ehrhardt1,4, Pia Banerjee1, Daniel A Mulrooney1,4, I-Chan Huang1, Kirsten K Ness1, Michael W Bishop4, Deokumar Srivastava3, Leslie L Robison1, Melissa M Hudson1,4, Kevin R Krull1,2.   

Abstract

BACKGROUND: To the authors' knowledge, few studies to date have examined long-term neurocognitive outcomes in survivors of childhood soft-tissue sarcoma.
METHODS: A total of 150 survivors (41% of whom were female with a mean current age of 33 years [SD, 8.9 years] and a time since diagnosis of 24 years [SD, 8.7 years]) and 349 community controls (56% of whom were female with a mean current age of 35 years [SD, 10.2 years]) completed comprehensive neuropsychological testing, echocardiography, electrocardiography, pulmonary function tests, endocrine evaluation, and physical examination. Patient-reported outcomes of health-related quality of life (HRQOL) and social attainment were collected. Survivors were compared with norms and controls on neurocognitive outcomes using general linear models, and on HRQOL and social attainment using modified Poisson models. The impacts of treatment and chronic health conditions on outcomes were examined using multivariable general linear models (effect size was expressed as unstandardized β estimates that reflected the unit of change from a mean of 0 and an SD of 1) and modified Poisson models (effect size expressed as relative risks).
RESULTS: Compared with controls and population norms, survivors demonstrated lower performance on measures of verbal reasoning (mean z score, -0.45 [SD, 1.15]; P < .001) mathematics (mean z score, -0.63 [SD, 1.07]; P < .001), and long-term memory (mean z score, -0.37 [SD, 1.14]; P < .001). Cumulative anthracycline exposure (per 100 mg/m2 ) was found to be associated with poorer verbal reasoning (β = -0.14 z scores; P = .04), reading (β = -0.09 z score; P = .04), and patient-reported vitality (relative risk, 1.32; 95% CI, 1.09-1.59). Neurologic and neurosensory chronic conditions were associated with poorer mathematics (neurologic conditions: β = -0.63 z score [P = 0.02]; and hearing impairment: β = -0.75 z scores [P < 0.01]). Better cognitive performance was associated with higher social attainment.
CONCLUSIONS: Long-term survivors of soft-tissue sarcoma are at risk of neurocognitive problems and poor HRQOL associated with anthracycline treatment and chronic health conditions.
© 2020 American Cancer Society.

Entities:  

Keywords:  anthracycline and cognition; childhood soft-tissue sarcoma; health-related quality of life (HRQOL); neurocognition; survivorship

Mesh:

Substances:

Year:  2020        PMID: 31913509      PMCID: PMC7104616          DOI: 10.1002/cncr.32694

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Full Scale IQ (FSIQ) changes in children treated with whole brain and partial brain irradiation. A review and analysis.

Authors:  M Fuss; K Poljanc; E B Hug
Journal:  Strahlenther Onkol       Date:  2000-12       Impact factor: 3.621

Review 2.  Quality of life in survivors of childhood cancer: a systematic review of the literature (2001-2008).

Authors:  Janette McDougall; Miranda Tsonis
Journal:  Support Care Cancer       Date:  2009-06-02       Impact factor: 3.603

3.  Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma.

Authors:  Matthew J Ehrhardt; Daniel A Mulrooney; Chenghong Li; Malek J Baassiri; Kari Bjornard; John T Sandlund; Tara M Brinkman; I-Chan Huang; Deo Kumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  Cancer       Date:  2017-09-15       Impact factor: 6.860

4.  Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group.

Authors:  R B Raney; L Asmar; R Vassilopoulou-Sellin; M J Klein; S S Donaldson; J Green; R Heyn; M Wharam; A S Glicksman; E A Gehan; J Anderson; H M Maurer
Journal:  Med Pediatr Oncol       Date:  1999-10

Review 5.  Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction.

Authors:  Christopher D Aluise; Rukhsana Sultana; Jitbangjong Tangpong; Mary Vore; Daret St Clair; Jeffrey A Moscow; D Allan Butterfield
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

6.  Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.

Authors:  Shashi Raj; Vivian I Franco; Steven E Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

7.  Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide.

Authors:  Catherine E Jansen; Marylin J Dodd; Christine A Miaskowski; Glenna A Dowling; Joel Kramer
Journal:  Psychooncology       Date:  2008-12       Impact factor: 3.894

8.  Critical combinations of radiation dose and volume predict intelligence quotient and academic achievement scores after craniospinal irradiation in children with medulloblastoma.

Authors:  Thomas E Merchant; Jane E Schreiber; Shengjie Wu; Renin Lukose; Xiaoping Xiong; Amar Gajjar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-08-23       Impact factor: 7.038

Review 9.  Cognitive decline in heart failure.

Authors:  Kannayiram Alagiakrishnan; Darren Mah; Ali Ahmed; Justin Ezekowitz
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 10.  Cytotoxic effects of adriamycin on the central nervous system of the mouse--cytofluorescence and electron-microscopic observations after various modes of administration.

Authors:  L Bigotte; Y Olsson
Journal:  Acta Neurol Scand Suppl       Date:  1984
View more
  2 in total

1.  A vulnerable age group: the impact of cancer on the psychosocial well-being of young adult childhood cancer survivors.

Authors:  L M E van Erp; H Maurice-Stam; L C M Kremer; W J E Tissing; H J H van der Pal; A C H de Vries; M M van den Heuvel-Eibrink; B A B Versluys; M van der Heiden-van der Loo; G A Huizinga; M A Grootenhuis
Journal:  Support Care Cancer       Date:  2021-02-01       Impact factor: 3.359

2.  GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma.

Authors:  S Gallego; D Bernabeu; M Garrido-Pontnou; G Guillen; N Hindi; A Juan-Ribelles; C Márquez; C Mata; J Orcajo; G Ramírez; M Ramos; C Romagosa; D Ruano; P Rubio; R Vergés; C Valverde
Journal:  Clin Transl Oncol       Date:  2021-07-01       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.